KPV

Dalmasso et al. (PLoS One): KPV demonstrates significant anti-inflammatory effects in murine models of inflammatory bowel disease, suppressing NF-κB and MAPK pathways.

Study shows KPV inhibits p65RelA nuclear import, suppressing NF-κB inflammatory signaling in airway epithelial cells — relevant to respiratory and gut inflammation.

Hyaluronic acid-functionalized nanoparticle delivery of KPV enhances oral bioavailability and anti-inflammatory efficacy in colitis models, supporting clinical translation.

KPV selectively suppresses production of IL-1β, IL-6, IL-12, TNF-α, and IFN-γ in colonic epithelial and immune cells, with effects mediated via intracellular PepT1 transport.

Limited clinical evidence supports the use of performance-enhancing peptides in sports despite their growing popularity, a 2026 review found. The research highlighted significant potential risks, including cardiovascular strain and insulin resistance, alongside major challenges in regulation and anti-doping detection.

A 2026 retrospective study demonstrated that medical thoracoscopy achieved a 99.4% diagnostic yield in patients with undiagnosed exudative pleural effusions. The procedure showed an excellent safety profile, with malignancy identified as the most common underlying etiology.

A 2026 study demonstrated that a self-immolative peptide prodrug conjugate platform enabled the oral delivery of anti-inflammatory peptides KPV, Ac-QAW, and IRW. Researchers found that these conjugates exhibited high gastrointestinal stability and significantly increased targeted accumulation in mice with colitis and acute lung injury.

A 2026 machine learning analysis of rice-associated bacteria demonstrated that ABC-type oligopeptide transport systems are abundantly distributed in beneficial strains. The study found that AI models can accurately classify these microbes based on genetic markers responsible for nutrient transport and metabolic versatility.

A 2025 review demonstrated that host defense peptides, such as cathelicidins and defensins, exhibit immunomodulatory properties that may benefit inflammatory bowel disease research. The study found these peptides downregulate the NF-κB pathway and modulate cytokine release to help restore intestinal homeostasis.

A 2025 review found that tripeptides demonstrate the ability to stimulate fibroblast migration, enhance collagen deposition, and modulate inflammation. Researchers investigated specific peptides like GHK and KPV, highlighting their mechanisms in supporting extracellular matrix remodeling and angiogenesis during tissue repair.